Centrymed

company

About

Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform.

Details

Last Funding Type
Series A
Industries
Biotechnology,Health Care,Health Diagnostics,Medical Device
Founded date
Jan 1, 2017
Operating Status
Active

Centrymed focuses on the field of tumor treatment, and its self-developed dual-antibody platform. The company's independent intellectual property rights have solved the problems of drug drugability and toxic and side effects of antibody drugs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Centrymed has raised a total of — in funding over 2 rounds. Their latest funding was raised on Feb 9, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 9, 2022 Series A 7 Taikun Capital Detail

Investors

Number of Lead Investors
Number of Investors
1
7
Centrymed is funded by 7 investors. Taikun Capital and Binjiang District Government Fund Hang Gao Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Taikun Capital Yes Series A
Binjiang District Government Fund Hang Gao Investment Series A
Anji Maisheng Series A
Yxassets.com Series A
Guangzhou Yue Min Investment Series A
HongXin Venture Capital Series A
Chenghe Venture Capital Series A